Immune Checkpoint Inhibitor-Associated Acute Kidney Injury: A Single-Center Experience of Biopsy-Proven Cases
Journal of Clinical Medicine · 06.05.2025 · 14 (9) · 3231
DOI: 10.3390/jcm14093231 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Medicine, online erschienen am 06.05.2025. Verfasst von Andreas Kommer und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine I, University Medical Center of Johannes Gutenberg University, 55131 Mainz, Germany. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Else Kröner-Fresenius-Stiftung, Clinician Scientist Fellowship.
Abstract (Originalsprache)
Background
Immune checkpoint inhibitor therapy (ICI) has greatly changed cancer therapy in recent years. The main side effects are immune-related adverse events (irAEs) that can affect any organ system. With the widespread use of ICIs, even rare irAEs, like acute kidney injury due to ICI-induced nephritis (ICI-AKI), have become a more common complication.
Methods
All ICI-treated patients who underwent a kidney biopsy for AKI at a single academic center between January 2020 and December 2023 were analyzed.
Results
We identified twelve cases of biopsy-proven ICI-AKI. The median follow up was 11.5 months. All cases showed acute interstitial nephritis (AIN) on the biopsy. Melanoma was the most common cancer, and dual-checkpoint inhibition with Ipilimumab and Nivolumab was the most common regimen. Extrarenal irAEs were present in only 25% of cases. Two-thirds had concomitant medication with proton pump inhibitors (PPIs). Only four patients completely recovered their kidney function, and one patient remained on kidney replacement therapy.
Conclusions
AIN is a common cause of AKI in ICI-treated cancer patients. Although they respond well to steroid treatment, full restitution of kidney function occurs in less than half of the subjects. As ICIs are increasingly used in cancer management, more research on the prevention and treatment of ICI-associated AKI is needed.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Internal Medicine I, University Medical Center of Johannes Gutenberg University, 55131 Mainz, Germany.
ORCID-Profile: Andreas Kommer, Daniel Kraus, Julia Weinmann-Menke
Förderung
- Else Kröner-Fresenius-Stiftung
- Clinician Scientist Fellowship
Zitieren
APA
Kommer, A., Stortz, M., Kraus, D., & Weinmann-Menke, J. (2025). Immune Checkpoint Inhibitor-Associated Acute Kidney Injury: A Single-Center Experience of Biopsy-Proven Cases. Journal of Clinical Medicine, 14(9), 3231. https://doi.org/10.3390/jcm14093231
Vancouver
Kommer A, Stortz M, Kraus D, Weinmann-Menke J. Immune Checkpoint Inhibitor-Associated Acute Kidney Injury: A Single-Center Experience of Biopsy-Proven Cases. Journal of Clinical Medicine. 2025;14(9):3231. doi:10.3390/jcm14093231
BibTeX
@article{Kommer2025,
author = {Kommer, Andreas and Stortz, Marco and Kraus, Daniel and Weinmann-Menke, Julia},
title = {Immune Checkpoint Inhibitor-Associated Acute Kidney Injury: A Single-Center Experience of Biopsy-Proven Cases},
journal = {Journal of Clinical Medicine},
year = {2025},
volume = {14},
number = {9},
pages = {3231},
doi = {10.3390/jcm14093231}
}
EUVIMED